Associate Professor
The Ohio State University Wexner Medical Center
Disclosure: Gilead Sciences (Advisor or Review Panel member)ViiV Healthcare (Advisor or Review Panel member)
Dr. Carlos Malvestutto is a clinician-researcher with expertise in the prevention, treatment, and management of HIV and other viral infections. He is an Associate Professor in the Division of Infectious Diseases at The Ohio State University Wexner Medical Center. Dr. Malvestutto is a clinical investigator at the OSU Infectious Disease Clinical Trials Unit and is involved in multiple clinical trials in prevention, treatment and complications of HIV and COVID-19. He is the Vice-Chair of the multinational Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). He also serves as a member of the MACS/WIHS Cardiovascular Complications Working Group and is as a member of the HIV Medical Association (HIVMA) Ending the HIV Epidemic Working Group and of the Reservoirs, Remission and Cure Transformative Science Group of the AIDS Clinical Trials Group (ACTG). His areas of clinical research include cardiovascular complications of HIV, use of broadly neutralizing antibodies for HIV treatment and cure, and improving access to HIV, Hepatitis C, and COVID-19 treatment for underserved populations.
